AstraZeneca chief executive Pascal Soriot is pursuing a merger with American pharmaceutical giant Bristol Myers Squibb, potentially shifting the company's focus toward the United States. The proposed transaction follows years of growing friction between the Anglo-Swedish company and the United Kingdom government.
Soriot previously repelled a takeover attempt by Pfizer in 2014 and built AstraZeneca into the second-largest firm on the FTSE 100, positioned just behind HSBC. The company's work on immunology treatments established both Britain and Cambridge as global leaders in pharmaceuticals.
However, relations strained after former Prime Minister Keir Starmer's Labour administration failed to support a planned vaccination facility near Liverpool. The previous government also pursued back-door efforts to extract additional income from the pharmaceutical sector for the National Health Service.
In response, AstraZeneca expanded its commitments in America, securing a full listing on the New York Stock Exchange. Soriot also promised $50billion in United States investment during an Oval Office meeting, including a parallel research and development site in Cambridge, Massachusetts.
At present, AstraZeneca generates 43 per cent of its revenues from the United States. Merging with Bristol Myers Squibb, a firm valued at $133.4billion compared to GlaxoSmithKline's £77billion valuation, would signal growing American dominance over the business.
Government challenges and regulatory scrutiny
The potential deal represents a major test for Andy Burnham's government, Cabinet Secretary Antonia Romeo, and the Business Department. Critics warn that losing operational weight to America would deal an immeasurable blow to the science-based economy of Britain.
The transaction faces significant anti-trust questions in both healthcare systems. However, Soriot may rely on standing with President Donald Trump's White House, which previously allowed David Ellison's Paramount Skydance to complete a reverse takeover of media titan Warner Bros Discovery.
In the United Kingdom, regulatory approval could be eased by previous reforms at the Competition and Markets Authority introduced by former Chancellor Rachel Reeves to speed up economic growth. Successive governments have historically viewed major corporate acquisitions as proof that post-Brexit Britain remains open for business.
Financial markets reacted cautiously to the news, driving AstraZeneca shares down 9 per cent yesterday and wiping £18billion from its market value. Investors expressed concern over combining with a lower-valued partner and taking on significant integration risks.
Operational risks and commercial opportunities
Integrating the two businesses would require resolving executive roles, aligning transatlantic pay structures, and delivering substantial cost savings. Industry experience from the 2000 merger between Glaxo Wellcome and SmithKline Beecham showed that corporate disruption can last for years and delay drug releases.
Despite integration challenges, AstraZeneca would enter the transaction as the dominant partner. The Cambridge-based firm benefits from a strong oncology pipeline, established commercial exposure in China, and a sharp focus on research and development.
Acquiring the cancer drug portfolio of Bristol Myers Squibb would turn the combined entity into a global powerhouse in oncology, while adding its heart disease treatments would further strengthen product offerings. Nevertheless, questions remain over whether health authorities in the United States and the United Kingdom will accept such market dominance, or if the merger risks large-scale value destruction.
